PF-04457845

Phase 2Small molecule

Pfizer

PF-04457845 is one of 52 small molecule programs targeting Tourette syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tourette SyndromeActive, not recruiting

OsteoarthritisActive, not recruiting

Tourette SyndromePhase 1

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Ilaris

Novartis

Preclinical

2 2

Toradol

Roche

Preclinical

1 3

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 4

Bayer Aspirin

PF-04457845

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Glucophage

Boehringer Ingelheim

Preclinical

1 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Completed·YYale University·Phase 2·NCT01618656·70 enrolled

Tourette syndrome1 trial

FAAH Inhibitor Trial for Adults With Tourette Syndrome

Terminated·YYale University·Phase 1·NCT02134080·5 enrolled

Humans1 trial

Cannabinoid Augmentation of Fear Response in Humans

Completed·YYale University·Phase 1·NCT01665573·31 enrolled

Osteoarthritis1 trial

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Completed· Pfizer logo

Pfizer·Phase 2·NCT00981357·76 enrolled

Cannabis Use Disorder1 trial

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

Completed·YYale University·Phase 2·NCT03386487·228 enrolled

2 more indications

Post-Traumatic Stress Disorder1 trial

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02216097·14 enrolled

Unspecified1 trial

Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00918164·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PF-04457845. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-04457845 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-04457845. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-04457845

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Tourette syndrome1 trial

Humans1 trial

Osteoarthritis1 trial

Cannabis Use Disorder1 trial

Post-Traumatic Stress Disorder1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News